Langford Dale J, Paul Steven M, Cooper Bruce, Kober Kord M, Mastick Judy, Melisko Michelle, Levine Jon D, Wright Fay, Hammer Marilyn J, Cartwright Frances, Lee Kathryn A, Aouizerat Bradley E, Miaskowski Christine
Department of Physiological Nursing, School of Nursing, University of California, 2 Koret Way-N631Y, San Francisco, CA, 94143-0610, USA.
School of Medicine, University of California, San Francisco, CA, USA.
Support Care Cancer. 2016 Feb;24(2):605-614. doi: 10.1007/s00520-015-2819-1. Epub 2015 Jul 4.
The purposes of this study, in a sample of women with breast cancer receiving chemotherapy (CTX), were to identify subgroups of women with distinct experiences with the symptom cluster of pain, fatigue, sleep disturbance, and depressive symptoms and evaluate differences in demographic and clinical characteristics, differences in psychological symptoms, and differences in pain characteristics among these subgroups.
Patients completed symptom questionnaires in the week following CTX administration. Latent class profile analysis (LCPA) was used to determine the patient subgroups.
Three subgroups were identified: 140 patients (35.8 %) in the "low," 189 patients (48.3 %) in the "moderate," and 62 patients (15.9 %) in the "all high" latent class. Patients in the all high class had a lower functional status, a higher comorbidity profile, a higher symptom burden, and a poorer quality of life.
Study findings provide evidence of the utility of LCPA to explain inter-individual variability in the symptom experience of patients undergoing CTX. The ability to characterize subgroups of patients with distinct symptom experiences allows for the identification of high-risk patients and may guide the design of targeted interventions that are tailored to an individual's symptom profile.
本研究以接受化疗(CTX)的乳腺癌女性为样本,旨在识别在疼痛、疲劳、睡眠障碍和抑郁症状症状群方面有不同经历的女性亚组,并评估这些亚组在人口统计学和临床特征、心理症状以及疼痛特征方面的差异。
患者在接受CTX治疗后的一周内完成症状问卷。采用潜在类别分析(LCPA)来确定患者亚组。
识别出三个亚组:“低”潜在类别中有140名患者(35.8%),“中度”中有189名患者(48.3%),“全部高”潜在类别中有62名患者(15.9%)。“全部高”类别的患者功能状态较低、合并症情况较多、症状负担较重且生活质量较差。
研究结果证明了LCPA在解释接受CTX治疗患者症状体验个体间差异方面的实用性。对具有不同症状体验的患者亚组进行特征描述的能力有助于识别高危患者,并可能指导根据个体症状特征量身定制的针对性干预措施的设计。